1-(2-((4R,6S)-2,2-dimethyl-6-(4-nitrobenzyl)-1,3-dioxan-4-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-(2-((4R,6S)-2,2-dimethyl-6-(4-nitrobenzyl)-1,3-dioxan-4-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide
• 英文别名: 1-[2-[(4R,6S)-2,2-dimethyl-6-[(4-nitrophenyl)methyl]-1,3-dioxan-4-yl]ethyl]-5-(4-fluorophenyl)-N,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide
• 化学式: C₄₁H₄₂FN₃O₅
• 分子量: 675.8
• InChiKey: NULHUUDGMDEBGU-GPOMZPHUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.8
• 重原子数：
  50
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  98.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1,3-dioxoisoindolin-2-yl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 在 nickel(II) chloride hexahydrate 、 4,4'-二甲氧基-2,2'-联吡啶 、 magnesium bromide ethyl etherate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 1-(2-((4R,6S)-2,2-dimethyl-6-(4-nitrobenzyl)-1,3-dioxan-4-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide
  参考文献：
  名称：

  脱羧硼化

  摘要：

  用碳酸交换硼酸 碳键合硼酸及其酯被广泛用作偶联伙伴以形成碳-碳键。最近，这些化学品本身就引起了制药业的兴趣。李等人。报道了一种使用邻苯二甲酰亚胺活化剂用硼酸酯代替羧酸的多功能镍催化工艺。该反应非常适合复杂分子的后期修饰。作者使用这种方法生产了一种有效的体外人中性粒细胞弹性蛋白酶抑制剂，这是治疗炎症性肺病的一个重要目标。科学，这个问题 p。eaam7355 镍催化多种化合物中的羧酸基团被硼酸和酯取代。介绍 硼酸是一种在材料科学中具有巨大效用的官能团，化学传感器开发和药物发现。在药物化学中，硼酸已被用作各种结构基序（生物等排体）的替代品，以提高先导化合物的效力或药代动力学特征。然而，烷基硼酸的广泛掺入在很大程度上受到与其制备相关的挑战的阻碍。因此，目前只有两种烷基硼酸在临床上使用，即万珂（Velcade）和宁拉罗（Ninlaro）。很少有方法能够从容易获得的起始材料中提供烷基硼酸酯；大多数表现

  DOI：

  10.1126/science.aam7355

文献信息

• [EN] CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS<br/>[FR] RÉACTIONS DE BORYLATION DÉCARBOXYLATIVE CATALYSÉES PAR CU ET NI
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2018175173A1

  公开（公告）日：2018-09-27

  The invention is directed to methods of converting a carboxylic acid group in a compound, via a redox active ester, to a corresponding boronic ester by treatment with bis(pinacolato)diboron-alkyllithium complex in the presence of a ligand, a Ni(ll) salt or a copper salt, and an Mg(ll) salt, in the presence of an alkyllithium or a lithium hydroxide or alkoxide salt. The product pinacolato boronate ester can be cleaved to provide a boronic acid. The invention is also directed to methods of preparing various compounds of medical value comprising boronic acid groups, and to novel boronic-acid containing compounds of medicinal value, including an atorvastatin boronic acid analog, a vancomycin aglycone boronic acid analog, and boronic acid containing elastase inhibitors mCBK319, mCBK320, mCBK323, and RPX-7009.

  这项发明涉及通过使用双(邻菲罗)二硼烷基锂络合物在配体、Ni(Ⅱ)盐或铜盐以及Mg(Ⅱ)盐的存在下，处理化合物中的羧酸基，通过氧化还原活性酯将其转化为相应的硼酯酯。在存在烷基锂或氢氧化锂或烷氧化锂盐的情况下，所述产品邻菲罗硼酸酯酯可以被裂解以提供硼酸。该发明还涉及制备含硼酸基的医用价值化合物的方法，以及具有药用价值的新型含硼酸基化合物，包括阿托伐他汀硼酸类似物、万古霉素裸核硼酸类似物和含硼酸的弹性蛋白酶抑制剂mCBK319、mCBK320、mCBK323和RPX-7009。
• Cu- and Ni-catalyzed decarboxylative borylation reactions
  申请人：The Scripps Research Institute

  公开号：US11161859B2

  公开（公告）日：2021-11-02

  The invention is directed to methods of converting a carboxylic acid group in a compound, via a redox active ester, to a corresponding boronic ester by treatment with bis(pinacolato)diboron-alkyllithium complex in the presence of a ligand, a Ni(ll) salt or a copper salt, and an Mg(ll) salt, in the presence of an alkyllithium or a lithium hydroxide or alkoxide salt. The product pinacolato boronate ester can be cleaved to provide a boronic acid. The invention is also directed to methods of preparing various compounds of medical value comprising boronic acid groups, and to novel boronic-acid containing compounds of medicinal value, including an atorvastatin boronic acid analog, a vancomycin aglycone boronic acid analog, and boronic acid containing elastase inhibitors mCBK319, mCBK320, mCBK323, and RPX-7009.

  本发明涉及在配体、Ni(ll)盐或铜盐以及 Mg(ll) 盐、烷基锂或氢氧化锂或氧化烷基锂盐存在的情况下，通过氧化还原活性酯与双(频哪醇)二硼烷基锂络合物处理，将化合物中的羧酸基转化为相应的硼酸酯的方法。产物频哪醇硼酸酯经裂解后可得到硼酸。本发明还涉及制备含有硼酸基团的各种具有医疗价值的化合物的方法，以及具有医疗价值的新型含硼酸化合物，包括阿托伐他汀硼酸类似物、万古霉素苷元硼酸类似物和含硼酸的弹性蛋白酶抑制剂 mCBK319、mCBK320、mCBK323 和 RPX-7009。
• CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS
  申请人：The Scripps Research Institute

  公开号：US20220024949A1

  公开（公告）日：2022-01-27

  The invention is directed to methods of converting a carboxylic acid group in a compound, via a redox active ester, to a corresponding boronic ester by treatment with bis(pinacolato)diboron-alkyllithium complex in the presence of a ligand, a Ni(II) salt or a copper salt, and an Mg(II) salt, in the presence of an alkyllithium or a lithium hydroxide or alkoxide salt. The product pinacolato boronate ester can be cleaved to provide a boronic acid. The invention is also directed to methods of preparing various compounds of medical value comprising boronic acid groups, and to novel boronic-acid containing compounds of medicinal value, including an atorvastatin boronic acid analog, a vancomycin aglycone boronic acid analog, and boronic acid containing elastase inhibitors mCBK319, mCBK320, mCBK323, and RPX-7009.